A Phase II Study of Gemcitabine at Fixed Infusion Rate of 10 mg/m²/min with or without Immunotherapy in Advanced Renal Cancer

Abstract

Background: Advanced renal cancer remains a challenge for oncologists since no treatment other than surgery has demonstrated a clear survival advantage. Patients and Methods: Gemcitabine was given to suitable patients at a fixed infusion rate of 10 mg/m²/min. Eighteen patients received concomitant immunotherapy, mostly low doses of interleukin 2 (IL2). Results: Thirty patients were enrolled. The overall response rate was 14% (22% in the subset of patients treated with both chemotherapy and immunotherapy) with a median progression-free survival time of 4.1+ months. Toxicity was not mild, mostly fatigue, nausea and anaemia, even though not life threatening. Conclusion: Gemcitabine at the fixed infusion rate of 10 mg/m²/min with concomitant low doses of IL2 could be useful in the palliative treatment of symptomatic patients with renal carcinoma progressing after tyrosine kinases inhibitor.